Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Nikhil Munshi, MD, on the association between MRD and survival outcomes in multiple myeloma

Dr. Munshi, Professor of Medicine, Harvard Medical School, Director of Basic and Correlative Science, Dana-Farber Cancer Institute, on whether there is an association between minimal residual disease (MRD) and long-term survival outcomes in multiple myeloma (MM)

Tags: ASH Conference CoverageMultiple Myeloma

Published: 16 December 2019

Recent Videos

video

Charu Aggarwal, MD, MPH, on approach to Checkpoint Inhibitors as therapy in NSCLC Impact of COVID

Dr. Aggarwal, Assistant Professor of Medicine, University of Pennsylvania, discusses her approach to the use of Checkpoint Inhibitors as first ...

video

Charu Aggarwal, MD, MPH, on how the findings from the FLAURA and ADURA impact EGFR NSCLC management

Dr. Aggarwal, Assistant Professor of Medicine, University of Pennsylvania, explains how the findings from FLAURA and ADURA impact clinical management ...

video

Charu Aggarwal, MD, MPH, discusses the role of liquid biopsies in the management of NSCLC

Dr. Aggarwal, Assistant Professor of Medicine, University of Pennsylvania, discusses the role of liquid biopsies in the management of non-small ...

video

Charu Aggarwal, MD, MPH, describes her approach to managing an individual with ALK positive NSCLC

Dr. Aggarwal, Assistant Professor of Medicine, University of Pennsylvania, describes her approach to the management of an individual with ALK ...

video

Case Study: Platinum Sensitive Recurrent High-Grade Serous Ovarian Cancer

Dr. Slomovitz, Professor of Obstetrics and Gynecology, Florida International University, Gynecologic Oncologist, Broward Health, and Dr. Kamath, Gynecologic Oncology Fellow, ...

video

Leslie Popplewell, MD, provides perspective on the ELARA study investigating the use of Kymriah (tisagenlecleucel) in follicular lymphoma patients that have received at least 2 prior therapies

Dr. Popplewell, Clinical Associate Professor, City of Hope, provides perspective on the ELARA study presented at ASCO20 and EHA20 investigating ...

video

Leslie Popplewell, MD, provides thoughts on the unique MOA of the newly FDA approved tazemetostat

Dr. Popplewell, Clinical Associate Professor, City of Hope, provides thoughts on the unique MOA of the newly FDA approved tazemetostat ...

video

Leslie Popplewell, MD, provides thoughts on the role Yescarta (axicabtagene ciloleucel) will play in low grade NHL management

Dr. Popplewell, Clinical Associate Professor, City of Hope, provides thoughts, based on the evidence presented at ASCO20, on the role ...

video

Leslie Popplewell, MD, on impressions of the Alexander trial investigating AUTO3(CAR-T cell therapy) as DLBCL treatment

Dr. Popplewell, Clinical Associate Professor, City of Hope, shares impressions of the Alexander trial investigating AUTO3 (CAR-T cell therapy) as ...

video

Leslie Popplewell, MD, discusses the potential practice changing outcomes of the Keynote-204 study presented at ASCO20

Dr. Popplewell, Clinical Associate Professor, City of Hope, discusses potential practice changing outcomes of the Keynote-204 study presented at ASCO20 ...

Related Videos

video-image

Charu Aggarwal, MD, MPH, on approach to Checkpoint Inhibitors as therapy in NSCLC Impact of COVID

video-image

Charu Aggarwal, MD, MPH, describes her approach to managing an individual with ALK positive NSCLC

video-image

Charu Aggarwal, MD, MPH, discusses the role of liquid biopsies in the management of NSCLC

video-image

Charu Aggarwal, MD, MPH, on how the findings from the FLAURA and ADURA impact EGFR NSCLC management

video-image

Case Study: Platinum Sensitive Recurrent High-Grade Serous Ovarian Cancer

video-image

Leslie Popplewell, MD, discusses the potential practice changing outcomes of the Keynote-204 study presented at ASCO20

video-image

Leslie Popplewell, MD, on impressions of the Alexander trial investigating AUTO3(CAR-T cell therapy) as DLBCL treatment

video-image

Leslie Popplewell, MD, provides thoughts on the role Yescarta (axicabtagene ciloleucel) will play in low grade NHL management

video-image

Leslie Popplewell, MD, provides thoughts on the unique MOA of the newly FDA approved tazemetostat

video-image

Leslie Popplewell, MD, provides perspective on the ELARA study investigating the use of Kymriah (tisagenlecleucel) in follicular lymphoma patients that have received at least 2 prior therapies

video-image

Andrew Zelenetz, MD, provides thoughts on the potential practice changing outcomes of the Keynote-204 study

video-image

Andrew Zelenetz, MD, shares impressions of the Alexander trial investigating AUTO3 as treatment for DLBCL

video-image

Andrew Zelenetz, MD, examines whether Yescarta (axicabtagene ciloleucel) will play a significant role in low grade NHL management

video-image

Andrew Zelenetz, MD, shares some of the unique aspects in the clinical design of the BOVen study

video-image

Andrew Zelenetz, MD, provides the clinical progress and outcomes to date with the BOVen trial in CLL

video-image

Andrew Zelenetz, MD, provides thoughts on the unique MOA of the newly FDA approved tazemetostat

video-image

Andrew Zelenetz, MD, discusses the validity and availability of the EZH2 companion diagnostic test

video-image

Andrew Zelenetz, MD, describes the study presented at ASCO 20 exploring the CIBMTR analysis of PET scans

video-image

Rana McKay, MD, discusses the unmet needs for clinical trials addressing non-clear cell RCC

video-image

Rana McKay, MD, discusses factors considered when deciding which patients to get an I-O combo in RCC